Toshio Kubo1, Hiromi Watanabe2, Kiichiro Ninomiya2, Kenichiro Kudo3,4, Daisuke Minami4, Etsuko Murakami5, Nobuaki Ochi6, Takashi Ninomiya2,7, Daijiro Harada8, Masayuki Yasugi9, Eiki Ichihara2, Kadoaki Ohashi2, Kammei Rai2,10, Keiichi Fujiwara4, Katsuyuki Hotta2,11, Masahiro Tabata1, Yoshinobu Maeda12, Katsuyuki Kiura2. 1. Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan. 2. Allergy and Respiratory Medicine, Okayama University Hospital, Okayama. 3. Respiratory Medicine, Iwakuni Medical Center, Iwakuni. 4. Respiratory Medicine, Okayama Medical Center, Okayama. 5. Respiratory Medicine, Japanese Red Cross Society Himeji Hospital, Himeji. 6. General Internal Medicine 4, Kawasaki Medical School, Okayama. 7. Health Service Center, Okayama University, Okayama. 8. Respiratory Medicine, Shikoku Cancer Center, Matsuyama. 9. Respiratory Medicine, Chugoku Central Hospital, Fukuyama. 10. Hospital-based Cancer registry division, Okayama University Hospital, Okayama. 11. Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama. 12. Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama.
Abstract
OBJECTIVES: Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged ≥65 years, but the effects in patients aged ≥75 years are controversial. We performed multicenter, collaborative and retrospective analyses of immune checkpoint inhibitor efficacy and safety in non-small cell lung cancer patients aged ≥75 years. METHODS: We retrospectively studied 434 advanced non-small cell lung cancer patients who received immune checkpoint inhibitors from December 2015 to December 2017, and retrospectively applied the Geriatric (G) 8 screening tool with medical records. RESULTS: Of the 434 patients who received immune checkpoint inhibitors, 100 were aged ≥75 years. Five patients with performance status 3 were omitted from the final analysis. Immune checkpoint inhibitors were given as a first-line treatment to 20 patients. The objective response rates, median progression-free survival rates and median survival times were 35.0%, 6.1 months and 10.7 months for first-line treatment, and 20.0%, 2.9 months and 14.7 months for second- or later-line treatments, respectively. The median modified G8 score was 11.0. The median survival time was longer in the high modified G8 (≥12.0) group than in the low modified G8 (≤11.0) group (18.7 vs. 8.7 months; P = 0.02). Likewise, the median survival time was 15.5 months (performance status 0-1) vs. 3.2 months (performance status 2) (P < 0.01). The grade ≥ 2 immune-related adverse events incidence was 36.8%. CONCLUSIONS: In this study, immune checkpoint inhibitors were effective and tolerable for patients aged ≥75 years. The modified G8 screening tool and performance status were associated with the outcome of older non-small cell lung cancer patients treated with immune checkpoint inhibitors.
OBJECTIVES: Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged ≥65 years, but the effects in patients aged ≥75 years are controversial. We performed multicenter, collaborative and retrospective analyses of immune checkpoint inhibitor efficacy and safety in non-small cell lung cancerpatients aged ≥75 years. METHODS: We retrospectively studied 434 advanced non-small cell lung cancerpatients who received immune checkpoint inhibitors from December 2015 to December 2017, and retrospectively applied the Geriatric (G) 8 screening tool with medical records. RESULTS: Of the 434 patients who received immune checkpoint inhibitors, 100 were aged ≥75 years. Five patients with performance status 3 were omitted from the final analysis. Immune checkpoint inhibitors were given as a first-line treatment to 20 patients. The objective response rates, median progression-free survival rates and median survival times were 35.0%, 6.1 months and 10.7 months for first-line treatment, and 20.0%, 2.9 months and 14.7 months for second- or later-line treatments, respectively. The median modified G8 score was 11.0. The median survival time was longer in the high modified G8 (≥12.0) group than in the low modified G8 (≤11.0) group (18.7 vs. 8.7 months; P = 0.02). Likewise, the median survival time was 15.5 months (performance status 0-1) vs. 3.2 months (performance status 2) (P < 0.01). The grade ≥ 2 immune-related adverse events incidence was 36.8%. CONCLUSIONS: In this study, immune checkpoint inhibitors were effective and tolerable for patients aged ≥75 years. The modified G8 screening tool and performance status were associated with the outcome of older non-small cell lung cancerpatients treated with immune checkpoint inhibitors.
Authors: Cheryl P Bruijnen; José J Koldenhof; Rik J Verheijden; Frederiek van den Bos; Mariëlle H Emmelot-Vonk; Petronella O Witteveen; Karijn P M Suijkerbuijk Journal: Cancer Date: 2022-04-19 Impact factor: 6.921
Authors: Vincent Vinh-Hung; Olena Gorobets; Andre Duerinkcx; Suresh Dutta; Eromosele Oboite; Joan Oboite; Ahmed Ali; Thandeka Mazibuko; Ulf Karlsson; Alexander Chi; David Lehrman; Omer Hashim Mohammed; Mohammad Mohammadianpanah; Gokoulakrichenane Loganadane; Natalia Migliore; Maria Vasileiou; Nam P Nguyen; Huan Giap Journal: Transl Cancer Res Date: 2022-09 Impact factor: 0.496